Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

被引：33

作者：

Cornelissen, Robin ^{[1
]}

Prelaj, Arsela ^{[2
,3
]}

Sun, Sophie ^{[4
]}

Baik, Christina ^{[5
]}

Wollner, Mirjana ^{[6
]}

Haura, Eric B. ^{[7
]}

Mamdani, Hirva ^{[8
,9
]}

Riess, Jonathan W. ^{[10
,11
]}

Cappuzzo, Federico ^{[12
]}

Garassino, Marina C. ^{[13
]}

Heymach, John V. ^{[14
]}

Socinski, Mark A. ^{[15
]}

Leu, Szu-Yun ^{[16
]}

Bhat, Gajanan ^{[16
]}

Lebel, Francois ^{[16
]}

Le, Xiuning ^{[14
]}

机构：

[1] Erasmus MC Canc Inst, Pulm Med, Rotterdam, Netherlands

[2] Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Ist Nazl Tumori Milano, Med Oncol, Milan, Italy

[3] Politecn Milan, Dept Elect Informat & Bioengn, Milan, Italy

[4] British Columbia Canc Ctr, Med Oncol, Vancouver, BC, Canada

[5] Seattle Canc Ctr Alliance, Seattle, WA USA

[6] Rambam Hlth Care Campus, Med Oncol, Haifa, Israel

[7] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[8] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA

[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Dept Internal Med, Sacramento, CA USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[12] Natl Canc Inst IRCCS Regina Elena, Dept Oncol, Rome, Italy

[13] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[14] Univ Texas MD Anderson Canc Ctr Houston, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[15] AdventHlth Canc Inst, Thorac Oncol Program, Orlando, FL USA

[16] Spectrum Pharmaceut, Res Dev, Irvine, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 08期

关键词：

KINASE DOMAIN; ANTITUMOR-ACTIVITY; SOMATIC MUTATIONS; CANCER; EGFR; HM781-36B; INHIBITOR;

D O I：

10.1016/j.jtho.2023.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1031 / 1041

页数：11

共 28 条

[1] Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models [J].

Cha, Mi Young ;

Lee, Kwang-Ok ;

Kim, Mira ;

Song, Ji Yeon ;

Lee, Kyu Hang ;

Park, Jongmin ;

Chae, Yun Jung ;

Kim, Young Hoon ;

Suh, Kwee Hyun ;

Lee, Gwan Sun ;

Park, Seung Bum ;

Kim, Maeng Sup .

INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (10) :2445-2454

[2] Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu [J].

De Greve, J. ;

Teugels, E. ;

Geers, C. ;

Decoster, L. ;

Galdermans, D. ;

De Mey, J. ;

Everaert, H. ;

Umelo, I. ;

In't Veld, P. ;

Schallier, D. .

LUNG CANCER, 2012, 76 (01) :123-127

[3] First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). [J].

Doebele, Robert Charles ;

Riely, Gregory J. ;

Spira, Alexander I. ;

Horn, Leora ;

Piotrowska, Zofia ;

Costa, Daniel Botelho ;

Neal, Joel W. ;

Zhang, Steven ;

Reichmann, William ;

Kerstein, David ;

Li, Shuanglian ;

Janne, Pasi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[4] Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) [J].

Dziadziuszko, Rafal ;

Smit, Egbert F. ;

Dafni, Urania ;

Wolf, Juergen ;

Wasag, Bartosz ;

Biernat, Wojciech ;

Finn, Stephen P. ;

Kammler, Roswitha ;

Tsourti, Zoi ;

Rabaglio, Manuela ;

Ruepp, Barbara ;

Roschitzki-Voser, Heidi ;

Stahel, Rolf A. ;

Felip, Enriqueta ;

Peters, Solange .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) :1086-1094

[5]

Ference JD, 2009, AM FAM PHYSICIAN, V79, P135

[6]

Food and Drug Administration, FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

[7] HER kinase inhibition in patients with HER2-and HER3-mutant cancers [J].

Hyman, David M. ;

Piha-Paul, Sarina A. ;

Won, Helen ;

Rodon, Jordi ;

Saura, Cristina ;

Shapiro, Geoffrey I. ;

Juric, Dejan ;

Quinn, David I. ;

Moreno, Victor ;

Doger, Bernard ;

Mayer, Ingrid A. ;

Boni, Valentina ;

Calvo, Emiliano ;

Loi, Sherene ;

Lockhart, Albert C. ;

Erinjeri, Joseph P. ;

Scaltriti, Maurizio ;

Ulaner, Gary A. ;

Patel, Juber ;

Tang, Jiabin ;

Beer, Hannah ;

Selcuklu, S. Duygu ;

Hanrahan, Aphrothiti J. ;

Bouvier, Nancy ;

Melcer, Myra ;

Murali, Rajmohan ;

Schram, Alison M. ;

Smyth, Lillian M. ;

Jhaveri, Komal ;

Li, Bob T. ;

Drilon, Alexander ;

Harding, James J. ;

Iyer, Gopa ;

Taylor, Barry S. ;

Berger, Michael F. ;

Cutler, Richard E., Jr. ;

Xu, Feng ;

Butturini, Anna ;

Eli, Lisa D. ;

Mann, Grace ;

Farrell, Cynthia ;

Lalani, Alshad S. ;

Bryce, Richard P. ;

Arteaga, Carlos L. ;

Meric-Bernstam, Funda ;

Baselga, Jose ;

Solit, David B. .

NATURE, 2018, 554 (7691) :189-194

[8]

Ingelheim Boehringer, AF NSCLC HER2 MUT

[9] Antitumor Activity of HM781-36B, Alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells [J].

Kang, Mi Hyun ;

Moon, Sung Ung ;

Sung, Ji Hea ;

Kim, Jin Won ;

Lee, Keun Wook ;

Lee, Hye Seung ;

Lee, Jong Seok ;

Kim, Jee Hyun .

CANCER RESEARCH AND TREATMENT, 2016, 48 (01) :355-364

[10] Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors [J].

Kris, M. G. ;

Camidge, D. R. ;

Giaccone, G. ;

Hida, T. ;

Li, B. T. ;

O'Connell, J. ;

Taylor, I. ;

Zhang, H. ;

Arcila, M. E. ;

Goldberg, Z. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1421-1427

← 1 2 3 →